Navigation Links
Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
Date:4/30/2009

HOPKINTON, Mass., April 30 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE; the Company) announced today that on April 24, 2009 it entered into an Amendment to License Agreement (Amendment) with BioAxone Therapeutic, Inc. (BioAxone), pursuant to which the license agreement between the Company and BioAxone originally executed in December 2006 and amended in March 2007 (the Cethrin License) was further amended. The Amendment replaces all of the pre-commercial financial and performance-related milestones contained in the Cethrin License with a formula-based approach to sharing any and all income generated under a sub-license. The Amendment provides that the Company will use reasonable commercial efforts to enter into a sub-license Agreement for the compounds and technology covered by the Cethrin License. In the event that the Company fails to sub-license its rights under the Cethrin License within a specified time period, the Company retains a right to receive a smaller portion of any license revenue that BioAxone generates after the Cethrin License, as amended, terminates. The Amendment also provides for the mutual release of claims that each party had previously alleged against the other under the Cethrin License.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )

"We are pleased with the amended agreement with BioAxone. With our recent progress with Altropane(R) and our Phase III molecular imaging program, a significant portion of our resources must be devoted to completing pivotal clinical trials, getting FDA approval and establishing manufacturing and commercialization partnerships for Altropane," stated Peter Savas, Chairman and CEO of Alseres. Mr. Savas continued: "We are deeply committed to the continued clinical development of Cethrin to treat patients with acute spinal cord injury. In the current environment, we believe that finding a strong development and commercialization partner for Cethrin is the best path forward to ensure that it is developed in a focused, efficient manner while Alseres concentrates on advancing Altropane toward market approval in the U.S. The amended agreement enables Alseres and BioAxone to work together on this partnering effort without the distraction of an arbitration procedure."

Cethrin License Background

In December 2006, the Company entered into the Cethrin License (as amended in March 2007), pursuant to which the Company was granted an exclusive, worldwide license to develop and commercialize specified compounds including, but not limited to, Cethrin, as further defined in the Cethrin License. The Cethrin License called for the Company to conduct development and commercialization activities of Cethrin and to pay certain pre-commercialization milestones and on-going royalties on sales of Cethrin when and if approved for marketing. The Amendment changes the pre-commercialization milestones and on-going royalty terms to an income-sharing approach.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of diagnostic and therapeutic products primarily for disorders in the central nervous system (CNS). The Company has a robust molecular imaging development program targeting diagnosis of Parkinsonian Syndromes and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's disease. The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company's ability to obtain financing, the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Alseres, Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.

    Contact:
    Ken Rice - 508-497-2360 ext. 226
    Alseres Pharmaceuticals, Inc.
    krice@alseres.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
5. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
6. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
7. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
8. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
9. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
10. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
11. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: